BioVersys AG (SWX:BIOV)

Switzerland · Delayed Price · Currency is CHF

26.30

-0.70 (-2.59%)

At close: Jun 22, 2026

-25.28% (1Y)

Market Cap	153.39M -26.0%
Revenue (ttm)	3.18M +161.7%
Net Income	-21.83M
EPS	-3.89
Shares Out	5.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	27.10
Previous Close	27.00
Day's Range	26.30 - 27.10
52-Week Range	21.20 - 36.00
Beta	n/a
Analysts	Strong Buy
Price Target	58.26 (+121.52%)
Earnings Date	Sep 3, 2026

About BioVersys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ans... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 33

Stock Exchange SIX Swiss Exchange

Ticker Symbol BIOV

Full Company Profile

Financial Performance

In 2025, BioVersys AG's revenue was 3.18 million, an increase of 161.75% compared to the previous year's 1.21 million. Losses were -21.83 million, 16.6% more than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for BIOV stock is "Strong Buy." The 12-month stock price target is CHF 58.26, which is an increase of 121.52% from the latest price.

Price Target

CHF 58.26

(121.52% upside)

Analyst Consensus: Strong Buy

Stock Forecasts